Development
SpringWorks Therapeutics, Inc.
SWTX
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -17.19% | -17.60% | -30.68% | -40.36% | -59.52% |
| Total Depreciation and Amortization | 117.91% | 110.98% | 95.74% | 86.48% | 56.12% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 31.48% | 34.82% | 47.98% | 66.63% | 90.44% |
| Change in Net Operating Assets | -101.53% | -112.55% | 302.68% | 5,132.93% | 644.49% |
| Cash from Operations | -37.90% | -39.44% | -13.93% | -12.37% | -26.34% |
| Capital Expenditure | 27.57% | -15.07% | -68.11% | -147.50% | -405.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 120.52% | -172.79% | -164.56% | -191.29% | -339.93% |
| Cash from Investing | 116.12% | -182.34% | -175.38% | -201.76% | -357.92% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -12.46% | -99.88% | 17,192.44% | 17,251.60% | 29,462.92% |
| Repurchase of Common Stock | -108.80% | -89.93% | -120.99% | -161.15% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -12.93% | -100.63% | 40,082.78% | 31,872.90% | 29,347.02% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 397.87% | -198.67% | 402.95% | 252.09% | 15.47% |